Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eng Huat Tan

Showing results (41-50 of 108) with videos related to

Pageof 11
Sort By:
Investigational New Drugs|September 14, 2007
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsBrigette Ma, Boon Cher Goh, Eng Huat Tan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 3, 2007
Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokersChee-Keong Toh, Fei Gao, Wan-Teck Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2006
Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entityChee-Keong Toh, Fei Gao, Wan-Teck Lim, et al.
The Lancet. Oncology|August 12, 2016
Novel therapeutic targets on the horizon for lung cancerWan-Ling Tan, Amit Jain, Angela Takano, et al.
Annals of the Academy of Medicine, Singapore|April 24, 2007
Survival of small-cell lung cancer and its determinants of outcome in SingaporeChee-Keong Toh, Siew-Wan Hee, Wan-Teck Lim, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)Balazs Halmos, Eng-Huat Tan, Ross A Soo, et al.
Pharmacogenetics and Genomics|August 15, 2006
Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patientsXiaoqiang Xiang, Srinivasa Rao Jada, Hui Hua Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 25, 2016
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary AdenocarcinomaTony Shu Kam Mok, Sarayut Lucien Geater, Wu-Chou Su, et al.
Annals of the Academy of Medicine, Singapore|June 10, 2008
Induction concurrent chemoradiotherapy using Paclitaxel and Carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer--Asian experienceSwee-Peng Yap, Wan-Teck Lim, Kian-Fong Foo, et al.
Pharmacogenetics and Genomics|January 7, 2017
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patientsCharlie Marvalim, Jing Xiang Gimson Wong, Natalia Sutiman, et al.
Pageof 11

Showing results (41-50 of 108) with videos related to

Sort By:
Pageof 11
Investigational New Drugs|September 14, 2007
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cellsBrigette Ma, Boon Cher Goh, Eng Huat Tan, et al.
Lung Cancer (Amsterdam, Netherlands)|February 3, 2007
Differences between small-cell lung cancer and non-small-cell lung cancer among tobacco smokersChee-Keong Toh, Fei Gao, Wan-Teck Lim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2006
Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entityChee-Keong Toh, Fei Gao, Wan-Teck Lim, et al.
The Lancet. Oncology|August 12, 2016
Novel therapeutic targets on the horizon for lung cancerWan-Ling Tan, Amit Jain, Angela Takano, et al.
Annals of the Academy of Medicine, Singapore|April 24, 2007
Survival of small-cell lung cancer and its determinants of outcome in SingaporeChee-Keong Toh, Siew-Wan Hee, Wan-Teck Lim, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo)Balazs Halmos, Eng-Huat Tan, Ross A Soo, et al.
Pharmacogenetics and Genomics|August 15, 2006
Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patientsXiaoqiang Xiang, Srinivasa Rao Jada, Hui Hua Li, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 25, 2016
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary AdenocarcinomaTony Shu Kam Mok, Sarayut Lucien Geater, Wu-Chou Su, et al.
Annals of the Academy of Medicine, Singapore|June 10, 2008
Induction concurrent chemoradiotherapy using Paclitaxel and Carboplatin combination followed by surgery in locoregionally advanced non-small cell lung cancer--Asian experienceSwee-Peng Yap, Wan-Teck Lim, Kian-Fong Foo, et al.
Pharmacogenetics and Genomics|January 7, 2017
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patientsCharlie Marvalim, Jing Xiang Gimson Wong, Natalia Sutiman, et al.
Pageof 11